CliffBio
small molecule

APONVIE

APREPITANT

Loss of exclusivitySeptember 2035latest FDA-listed patent expiry
CompanyHeron Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameAPONVIE
Active ingredientAPREPITANT
Strength32MG/4.4ML (7.2MG/ML)
Dosage formEMULSION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2022
Marketing statusRX

Listed patents

PatentExpiresType
10953018September 2035use U-3440
10624850September 2035use U-3440
9974794September 2035product
9808465September 2035use U-3440
9561229September 2035product
11744800September 2035product
11878074September 2035use U-3787
10500208September 2035product
9974793September 2035product
12290520September 2035product
12115254September 2035product
9974742September 2035product
11173118September 2035product
12115255September 2035product

More from Heron Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

APONVIE patent cliff — loss of exclusivity September 2035 | CliffBio